Dr Nozanin Yusufovna Yusufbekova, PSYD | |
99-128 Aiea Heights Dr Ste 704, Aiea, HI 96701-3940 | |
(808) 425-2625 | |
Not Available |
Full Name | Dr Nozanin Yusufovna Yusufbekova |
---|---|
Gender | Female |
Speciality | Psychologist - Clinical |
Location | 99-128 Aiea Heights Dr Ste 704, Aiea, Hawaii |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1124268248 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Dr Nozanin Yusufovna Yusufbekova, PSYD 99-128 Aiea Heights Dr Ste 704, Aiea, HI 96701-3940 Ph: (808) 425-2625 | Dr Nozanin Yusufovna Yusufbekova, PSYD 99-128 Aiea Heights Dr Ste 704, Aiea, HI 96701-3940 Ph: (808) 425-2625 |
News Archive
MO BIO Laboratories, Inc., the leader in microbial, stool, plant, and soil nucleic acid purification, announces the launch of the UltraClean-htp 96 Well Swab DNA Kit. The kit is designed for rapid mechanical lysis of microbial cells from low biomass and low inhibitor containing swabs, paper or filter paper for direct application to PCR for metagenomic analysis.
In a new study, Dartmouth researchers describe the structure of a protein called ToxT that controls the virulent nature of Vibrio cholerae, the bacteria that causes cholera. Buried within ToxT, the researchers were surprised to find a fatty acid that appears to inhibit ToxT, which prevents the bacteria from causing cholera.
During 2010-2011, University of Louisville Health Sciences Center faculty and students made an economic impact of more than $5.7 million in the four regions of Kentucky served by UofL Area Health Education Centers.
Delirium, or the medical term for experiencing sudden confusion, is upsetting for both older adults and their families. In fact, it is one of the most common complications older adults face after surgery (a time often referred to as the "post-operative" period).
Breathe Technologies, Inc., a manufacturer of innovative technology solutions for people with respiratory conditions, including chronic obstructive pulmonary disease and sleep apnea, announced today it has secured $23 million in Series C financing.
› Verified 2 days ago